Soluble epoxide hydrolase inhibition

Targeting multiple mechanisms of ischemic brain injury with a single agent

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Soluble epoxide hydrolase (sEH) is a key enzyme in the metabolic conversion and degradation of P450 eicosanoids termed epoxyeicosatrienoic acids (EETs). Genetic variations in the sEH gene, designated EPHX2, are associated with ischemic stroke risk. In experimental studies, sEH inhibition and gene deletion reduce infarct size after focal cerebral ischemia in mice. Although the precise mechanism of protection afforded by sEH inhibition remains under investigation, EETs exhibit a wide array of potentially beneficial actions in stroke, including vasodilation, neuroprotection, promotion of angiogenesis and suppression of platelet aggregation, oxidative stress and postischemic inflammation. Herein, we argue that by capitalizing on this broad protective profile, sEH inhibition represents a prototype 'combination therapy' targeting multiple mechanisms of stroke injury with a single agent.

Original languageEnglish (US)
Pages (from-to)179-199
Number of pages21
JournalFuture Neurology
Volume4
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Epoxide Hydrolases
Brain Injuries
Stroke
Eicosanoids
Gene Deletion
Brain Ischemia
Platelet Aggregation
Vasodilation
Oxidative Stress
Inflammation
Acids
Wounds and Injuries
Enzymes
Genes

Keywords

  • Cerebral blood flow
  • Cerebral ischemia
  • Combination therapy
  • Epoxyelcosatrienoic acids
  • Soluble epoxide hyrdolase
  • Stroke

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

@article{947ff667e40b41e0b291d82a1e523f1e,
title = "Soluble epoxide hydrolase inhibition: Targeting multiple mechanisms of ischemic brain injury with a single agent",
abstract = "Soluble epoxide hydrolase (sEH) is a key enzyme in the metabolic conversion and degradation of P450 eicosanoids termed epoxyeicosatrienoic acids (EETs). Genetic variations in the sEH gene, designated EPHX2, are associated with ischemic stroke risk. In experimental studies, sEH inhibition and gene deletion reduce infarct size after focal cerebral ischemia in mice. Although the precise mechanism of protection afforded by sEH inhibition remains under investigation, EETs exhibit a wide array of potentially beneficial actions in stroke, including vasodilation, neuroprotection, promotion of angiogenesis and suppression of platelet aggregation, oxidative stress and postischemic inflammation. Herein, we argue that by capitalizing on this broad protective profile, sEH inhibition represents a prototype 'combination therapy' targeting multiple mechanisms of stroke injury with a single agent.",
keywords = "Cerebral blood flow, Cerebral ischemia, Combination therapy, Epoxyelcosatrienoic acids, Soluble epoxide hyrdolase, Stroke",
author = "Jeffrey Iliff and Nabil Alkayed",
year = "2009",
doi = "10.2217/14796708.4.2.179",
language = "English (US)",
volume = "4",
pages = "179--199",
journal = "Future Neurology",
issn = "1479-6708",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Soluble epoxide hydrolase inhibition

T2 - Targeting multiple mechanisms of ischemic brain injury with a single agent

AU - Iliff, Jeffrey

AU - Alkayed, Nabil

PY - 2009

Y1 - 2009

N2 - Soluble epoxide hydrolase (sEH) is a key enzyme in the metabolic conversion and degradation of P450 eicosanoids termed epoxyeicosatrienoic acids (EETs). Genetic variations in the sEH gene, designated EPHX2, are associated with ischemic stroke risk. In experimental studies, sEH inhibition and gene deletion reduce infarct size after focal cerebral ischemia in mice. Although the precise mechanism of protection afforded by sEH inhibition remains under investigation, EETs exhibit a wide array of potentially beneficial actions in stroke, including vasodilation, neuroprotection, promotion of angiogenesis and suppression of platelet aggregation, oxidative stress and postischemic inflammation. Herein, we argue that by capitalizing on this broad protective profile, sEH inhibition represents a prototype 'combination therapy' targeting multiple mechanisms of stroke injury with a single agent.

AB - Soluble epoxide hydrolase (sEH) is a key enzyme in the metabolic conversion and degradation of P450 eicosanoids termed epoxyeicosatrienoic acids (EETs). Genetic variations in the sEH gene, designated EPHX2, are associated with ischemic stroke risk. In experimental studies, sEH inhibition and gene deletion reduce infarct size after focal cerebral ischemia in mice. Although the precise mechanism of protection afforded by sEH inhibition remains under investigation, EETs exhibit a wide array of potentially beneficial actions in stroke, including vasodilation, neuroprotection, promotion of angiogenesis and suppression of platelet aggregation, oxidative stress and postischemic inflammation. Herein, we argue that by capitalizing on this broad protective profile, sEH inhibition represents a prototype 'combination therapy' targeting multiple mechanisms of stroke injury with a single agent.

KW - Cerebral blood flow

KW - Cerebral ischemia

KW - Combination therapy

KW - Epoxyelcosatrienoic acids

KW - Soluble epoxide hyrdolase

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=67149084404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67149084404&partnerID=8YFLogxK

U2 - 10.2217/14796708.4.2.179

DO - 10.2217/14796708.4.2.179

M3 - Article

VL - 4

SP - 179

EP - 199

JO - Future Neurology

JF - Future Neurology

SN - 1479-6708

IS - 2

ER -